Harvard Bioscience (NASDAQ:HBIO) Given New $4.50 Price Target at Benchmark

Harvard Bioscience (NASDAQ:HBIO) had its price objective reduced by Benchmark from $5.50 to $4.50 in a research report released on Monday morning,Benzinga reports. They currently have a speculative buy rating on the medical instruments supplier’s stock.

Harvard Bioscience Stock Up 3.2 %

Shares of NASDAQ:HBIO opened at $0.61 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. Harvard Bioscience has a 52-week low of $0.56 and a 52-week high of $4.70. The firm has a market capitalization of $26.93 million, a P/E ratio of -1.85 and a beta of 1.46. The stock has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.95.

Institutional Trading of Harvard Bioscience

A number of hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in shares of Harvard Bioscience in the 3rd quarter worth about $30,000. Focus Partners Wealth purchased a new stake in Harvard Bioscience in the fourth quarter worth about $28,000. Avior Wealth Management LLC increased its stake in shares of Harvard Bioscience by 1,118.1% during the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 13,373 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Harvard Bioscience during the fourth quarter valued at approximately $35,000. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Harvard Bioscience in the 3rd quarter worth approximately $50,000. Institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.